• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Allurion Technologies Inc.

    6/18/25 5:10:21 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    S-8 1 d130343ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 18, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    ALLURION TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

     

    92-2182207

    (I.R.S. Employer

    Identification Number)

    11 Huron Drive

    Natick, MA

    (Address of Principal Executive Offices)

     

    01760

    (Zip Code)

    Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan

    Allurion Technologies, Inc. 2023 Employee Stock Purchase Plan

    (Full title of the plans)

    Shantanu Gaur

    Chief Executive Officer

    11 Huron Drive

    Natick, MA 01760

    (Name and address of agent for service)

    (508) 647-4000

    (Telephone number, including area code, of agent for service)

    Copies to:

    Danielle M. Lauzon

    Jeffrey A. Letalien

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    Telephone: (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This registration statement on Form S-8 relating to the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (the “2023 Plan”) and the Allurion Technologies, Inc. 2023 Employee Stock Purchase Plan (the “2023 ESPP”) (together the “Plans”) of Allurion Technologies, Inc. (the “Registrant”) registers an aggregate of 447,254 additional shares of common stock, par value $0.0001 per share (“common stock”), of the Registrant reserved under the Plans, representing (x) an increase of (i) 142,763 shares reserved under the 2023 Plan, effective January 1, 2024, and (ii) 229,948 shares reserved under the 2023 Plan, effective January 1, 2025, and (y) an increase of (i) 28,553 shares reserved under the 2023 ESPP, effective January 1, 2024, and (ii) 45,990 shares reserved under the 2023 ESPP, effective January 1, 2025, in each case by operation of the Plans’ “evergreen” provision and as adjusted for the reverse stock split of 1-for-25 effected by the Registrant effective as of January 3, 2025. This registration statement registers additional securities of the same class as other securities for which a registration statement on Form S-8 relating to the Plans has previously been filed and is effective. Accordingly, pursuant to General Instruction E, the information contained in the Registrant’s registration statement on Form S-8 (File No. 333-275126) is hereby incorporated by reference and made a part of this registration statement, except as presented below in Part II, Item 8. Exhibits.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description

     4.1    Form of Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2023).
     4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 31, 2024).
     4.3    Amended and Restated Bylaws of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2023).
     5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP (with respect to the Allurion Technologies, Inc. financial statements).
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page of this Registration Statement).
    99.1    Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan and form of award agreements (incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 filed with the SEC on October 20, 2023).
    99.2    Allurion Technologies, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.4 to the Registrant’s Registration Statement on Form S-8 filed with the SEC on October 20, 2023).
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Natick, Commonwealth of Massachusetts, on June 18, 2025.

     

    ALLURION TECHNOLOGIES, INC.

    By:

     

    /s/ Shantanu Gaur

    Name:

     

    Shantanu Gaur

    Title:

     

    Chief Executive Officer and Director

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Shantanu Gaur as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Shantanu Gaur

    Shantanu Gaur

       Chief Executive Officer and Director
    (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
       June 18, 2025

    /s/ Milena Alberti-Perez

    Milena Alberti-Perez

      

    Director

       June 18, 2025

    /s/ Michael Davin

    Michael Davin

      

    Director

       June 18, 2025

        

    Krishna Gupta

      

    Director

      

    /s/ Larson Douglas Hudson

    Larson Douglas Hudson

      

    Director

       June 18, 2025

    /s/ Omar Ishrak

    Omar Ishrak

      

    Director

       June 18, 2025

    /s/ Keith B. Johns II

    Keith B. Johns II

      

    Director

       June 18, 2025

    /s/ Nicholas Lewin

      

    Director

       June 18, 2025
    Nicholas Lewin      

    /s/ R. Jason Richey

         
    R. Jason Richey   

    Director

       June 18, 2025
    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allurion Technologies downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

      11/14/24 8:29:33 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • TD Cowen initiated coverage on Allurion Technologies with a new price target

      TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      10/2/24 7:13:57 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • ROTH MKM initiated coverage on Allurion Technologies with a new price target

      ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      9/6/24 7:25:38 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

      Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

      6/17/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Present at Jefferies Global Healthcare Conference

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

      5/29/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

      In 1,962 patients treated in France with the Allurion Program, muscle mass as a percentage of total body weight increased, on average, by 6.6% and fat mass decreased, on average, by 11% Company announces that shipments to France have resumed, and patient treatments are expected to resume next month Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l'Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025. The study, entitled "The Swallowable Gastric Balloon Program with AI Powe

      5/27/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    SEC Filings

    See more
    • SEC Form S-8 filed by Allurion Technologies Inc.

      S-8 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      6/18/25 5:10:21 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:04:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:02:23 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/17/25 6:36:58 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

      Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

      9/3/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

      Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

      8/20/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

      Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

      6/5/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:43:43 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:15:52 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

      SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      10/24/24 5:19:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Financials

    Live finance-specific insights

    See more
    • Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

      5/14/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

      5/5/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

      3/26/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care